AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01506193 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec
Description: One dose administered intramuscularly
Study NCT01506193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningitec
Description: One dose administered intramuscularly
Study NCT00685919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: 200 mg every 6 hours for 5 doses given orally
Study NCT00685919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: every 6 hours for 5 doses, given orally, and matching Carbidopa
Study NCT02742090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Umbralisib was administered as a tablet(s), orally once daily.
Study NCT01689064 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stamm Approach
Study NCT01689064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Septectomy
Study NCT01272557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).
Study NCT01272557 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Sorafenib 400 mg bid (oral) continuously
Study NCT02964728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Neurotoxin Type A
Description: topical injection
Study NCT02964728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: topical injection
Study NCT02444533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal Bupivacaine
Description: Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
Study NCT02161952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.
Study NCT02161952 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched equivalent placebo
Study NCT04104646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF6563
Description: Sublingual CHF6563 administration at starting dose of 10 µg/kg q8
Study NCT04434560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given at the FDA-approved dose of 3 mg/kg.
Study NCT04434560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab will be given at the FDA-approved dose of 1 mg/kg.
Study NCT02724046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Single-dose oral ciprofloxacin
Study NCT01029054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib, lenalidomide plus dexamethasone
Description: Phase I: Carfilzomib will be administered at the dosage assigned for the subject's cohort as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone 40 mg will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push.
Study NCT01029054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carfilzomib, lenalidomide plus dexamethasone
Description: Phase II: Carfilzomib will be administered at the Maximum Tolerated Dose (MTD) established in Phase I as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).~Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.~Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push on Days 1, 8, 15, and 22 as follows: Cycles 1-4: 40 mg; Cycles 5-8: 20 mg; and Cycles 9 and higher: 10 mg.
Study NCT02656433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Random Noise Stimulation
Description: A special Helmet supply weak electrical currents in the head
Study NCT02656433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Standard of care physiotherapy aimed to the motor impairment the subject presents
Study NCT02656433 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiotherapy
Description: Standard of care physiotherapy aimed to the motor impairment the subject presents
Study NCT03621644 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic MRI-guided On-table Adaptive Radiation Therapy
Description: Radiation therapy will be delivered with an integrated magnetic resonance imaging (MRI)-guided radiotherapy delivery system (ViewRay MRIdian or MRIdian Linac). The prescribed dose will be 50 Gray (Gy) in 5 fractions. Stereotactic body radiotherapy (SBRT) fractions will be delivered at least twice per week, and with at least 18 hours between fractions. Each participant will be aligned in the treatment system with MRI image-guidance. On-table adaptive re-planning will be used when clinically indicated. In all patients, real-time MRI imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam as necessary.
Study NCT02654626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-7072
Description: Drug Intervention
Study NCT02641626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urgent Coronary Angiography
Description: Diagnostic test for the evaluation of the coronary vasculature.
Study NCT02641626 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deferred Coronary Angiography
Description: Diagnostic test for the evaluation of the coronary vasculature.
Study NCT02965729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based weight management
Description: The Our Lifestyles, Our Lives family-based weight management intervention consisted of 10 weekly 90-minute group sessions focused on physical activity, nutrition, and behavioral modification. Parents and siblings were encouraged to join the participant in these sessions. Sessions were interactive and included cooking demonstrations, light to moderate intensity physical activity that engaged all family members, and behavioral counseling sessions in both mixed (parent and child) and parent-only format.
Study NCT02965729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer
Description: In addition to participating in the family-based weight management intervention, participants were given a pedometer (Omron HJ-324U, Omron Healthcare, Lake Forest, IL) and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10.
Study NCT02965729 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized step goals
Description: In addition to participating in the family-based weight management intervention, participants were given a step goal to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
Study NCT00725361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Study NCT04104646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Oral morphine administration at starting dose of 0.07 mg/kg q4
Study NCT04104646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHF6563 matched placebo
Description: Sublingual CHF6563 matched placebo administration
Study NCT04104646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine matched placebo
Description: Oral morphine matched placebo administration
Study NCT03346135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo standard of care ASCT with a conditioning regimen of melphalan
Study NCT03346135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03346135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03346135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Undergo standard of care ASCT with a conditioning regimen of melphalan
Study NCT00793052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodalac, Etoricoxib and Dexamethasone
Description: Dexamethasone sodium phosphate 8 mg 1 hour before the extraction, 4 mg the day after the extraction and another 4 mg at second day to the extraction.~Etoricoxib 120 mg 1 hour before the extraction, 120 mg the day after the extraction and another 120 mg at second day to the extraction.~Etodalac 600 mg 1 hour before the extraction, 600 mg the day after the extraction and another 600 mg at second day to the extraction.
Study NCT00820235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsseoSpeed™
Description: OsseoSpeed™ implant
Study NCT00820235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NobelSpeedy™ Replace®
Description: NobelSpeedy™ Replace® implant
Study NCT00820235 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NanoTite™ Certain® PREVAIL®
Description: NanoTite™ Certain® PREVAIL® implant
Study NCT03940313 — intervention group
Intervention type: PROCEDURE
Intervention: Prolotherapy
Description: Musculoskeletal injection of lidocaine + 15% dextrose into damaged tissue
Study NCT01783106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: experimental
Study NCT01783106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: experimental
Study NCT01783106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: oral
Study NCT01783106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: active comparator
Study NCT00850902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Humidity (HH)
Description: High Humidity Level
Study NCT00850902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Humidity
Description: Moderate Humidity Level
Study NCT02273180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine HOE901
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
Study NCT02273180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine HOE901
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
Study NCT02654626 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT01833338 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Imaging
Description: All patients undergo non-invasive (MSCT) and invasive (IVUS, OCT) imaging
Study NCT02899780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultraviolet light emitting optical fiber
Description: A ultraviolet light emitting optical fiber will be threaded through the existing catheter and withdrawn.
Study NCT06034548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: diabetes and hypertension self-management
Description: 12-weeks of 75 minutes of educational sessions
Study NCT02191553 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group relaxation techniques
Description: Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
Study NCT02191553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation
Description: Following Kristin Neff protocol
Study NCT02191553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body scan
Description: Body scan: Attention being directed with detailed awareness to every part of the body for a sustained period of time.
Study NCT02191553 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting practice
Description: In the sitting exercise, participants are guided to pay attention to a certain range of still points, starting with attention to breathing. In this exercise attention is fully concentrated on a single object: the sensation attached to breathing. If the mind wanders or is distracted by an external stimulus, attention is gently returned to sensations derived from breathing.
Study NCT00965432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STX107
Description: Single dose of an oral suspension
Study NCT00965432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STX107
Description: Single dose of an oral suspension
Study NCT04632875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loving-Kindness Meditation
Description: Approximately 15-minute sessions are administered 6 days per week
Study NCT04632875 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Meditation
Description: Approximately 15-minute sessions are administered 6 days per week
Study NCT04253743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nevada Healthy, Hunger-Free Kids Demonstration Benefits
Description: SNAP households with children under age 5 incomes below 75% of the federal poverty level living in Clark County, Nevada received $40 in extra SNAP benefits per eligible child, and access to case management and nutrition education.
Study NCT00322348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 3.6 mg intramuscular depot injection given every 4 weeks
Study NCT00322348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: 10.8 mg intramuscular depot injection given every 12 weeks
Study NCT04164992 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUSRA electrode needle connected to a radiofrequency generator (VIVA RF generator; STARmed, Seoul, S. Korea)
Description: The operative needle (EUSRA-STARMED) is a novel monopolar 18 gauge radiofrequency ablation (RFA) electrode that is placed in the echoendoscope operative channel. It is 140 cm long with a sharp conical 1 cm tip for energy delivery. The needle is associated with an internal cooling system connected via a pump to an external cold saline solution source (0 °C) that prevents the charring of the tip and improves the ablation accuracy.
Study NCT02248298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2h-AFL-PDT
Description: AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 2 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
Study NCT02248298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3h-AFL-PDT
Description: AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
Study NCT02248298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3hr-MAL-PDT
Description: an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2.
Study NCT01986465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depomedrol
Study NCT01986465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03974542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone outreach
Description: The navigator should make at least five (5) attempts to reach the participants on different days (at least one (1) attempt in weekend) and different time slots (at least one (1) attempt each in am, pm and evening). If the navigator only reached voice mail after the 1-month intervention period, a standard script will be read and a contact number will be provided.
Study NCT02615574 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: αDC1 vaccine
Description: Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
Study NCT02615574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKM
Description: Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
Study NCT02288468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vercise™ Deep Brain Stimulation System
Description: The Vercise™ DBS System includes a Stimulator with DBS Leads for unilateral or bilateral stimulation. There are also DBS Extensions that allow the DBS Leads mounted in the skull to be extended to reach the Stimulator implanted near the clavicle.~The rechargeable Vercise DBS System utilizes current steering across eight contacts per DBS Lead to provide precise positioning of stimulation. The Stimulator is controlled by a handheld Remote Control, and can be interfaced with a Clinician's Programmer using the Bionic Navigator™ Software. Periodically, the Stimulator battery must be replenished with an RF (radiofrequency) charging device provided in the Patient DBS Charging Kit.
Study NCT01292239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule taken by mouth once daily for 12 weeks
Study NCT01292239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 100-mg capsule taken by mouth once daily for 12 weeks
Study NCT01292239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a (pegIFN alfa-2a)
Description: PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.
Study NCT01292239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to \<=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is \<=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
Study NCT01834131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Intervention
Description: The comprehensive intervention includes physician education, a community health worker home intervention and a mobile health intervention. Please see Arm Description for details.
Study NCT00262821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV
Study NCT00262821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00262821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirapazamine
Description: Given IV
Study NCT01789554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MLS dispatch for bystander CPR